An experimental gene therapy based on the prime editing technique could become an effective treatment for alternating hemiplegia of childhood, a severe and currently incurable rare disease. David ...

Hengrui Pharmaceuticals Co. Ltd. is out-licensing to GSK plc its potential best-in-class phase I phosphodiesterase 3 and 4 inhibitor (HRS-9821) for treating chronic obstructive pulmonary disease along ...

Trinity Biotech plc recently unveiled CGM+, an AI-native, wearable biosensor that goes beyond traditional continuous glucose monitors and tracks glucose levels, cardiovascular activity and body ...

With more-than-satisfying phase III data in hand, Minneapolis-based Celcuity Inc. is eyeing an NDA submission in the fourth quarter of this year for gedatolisib (geda) in breast cancer. Shares of the ...

While U.S. government cost-cutting seems to be the Trump administration’s priority that consumes all others, some Republican ...

Thoracic aortic dissection can progress to a highly lethal cardiac emergency, but it cannot usually be detected in early stages, so suitable biomarkers of progression are needed. Levels of C-reactive ...

Researchers at the Fred Hutchinson Cancer Research Center found that autoantibodies targeting the exoproteome reshaped ...

An advisory committee for the U.S. Centers for Medicare & Medicaid Services endorsed a series of patient- and ...

Researchers from Biotiche Drug Discovery Srl and collaborators have discovered that modulating the activity of a specific ...

The U.S. FDA has cleared Zymeworks Inc.’s IND application for ZW-251, a novel glypican-3 (GPC3)-targeted antibody-drug ...

The chaperone protein Hsp90 is overexpressed in many cancers, where it helps protect and drive cell proliferation by ...

Activating apoptosis of tumor cells by binding a soluble form of the membrane protein TRAIL to its surface receptors DR4 and ...